Previous 10 | Next 10 |
ANI Pharmaceuticals (NASDAQ: ANIP ): Q4 Non-GAAP EPS of $1.08 misses by $0.10 ; GAAP EPS of -$0.41 misses by $0.56 . More news on: ANI Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
BAUDETTE, Minn. , Feb. 27, 2020 /PRNewswire/ -- For the full year ended December 31, 2019 : Record net revenues of $206.5 million , an increase of 2.5% versus 2018 GAAP net income of $6.1 million and diluted GAAP earnings per share of $0.50 Adjusted non-GAAP EBITDA o...
BAUDETTE, Minn. , Feb. 20, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its fourth quarter and year-to-date 2019 financial results on Thursday, February 27, 2020 , before the opening of the U.S. financial markets. Th...
BAUDETTE, Minn. , Feb. 12, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Sulfamethoxazole and Trimethoprim Oral Suspension USP 200 mg/40 mg per 5 mL. The current annual market for this product is approximately $29 million , ...
Corticotropin Gel Recommercialization Strategy In December 2015, ANI Pharmaceuticals ( ANIP ) acquired Cortropin Gel Injection (NDA #008975), 40 units/mL and 80 units/mL and for Cortropin-Zinc Injection (NDA #009854), 40 units/mL from Merck and Co. Inc. ( MRK ), for $75 million and a percent...
BlackRock Inc. ( BLK ) and Vanguard Group Inc. represent the world’s two largest Asset Management Companies. According to 2019 Q3 filing, BlackRock had $6.96 trillion USD in assets under management. While, according Vanguard , they had $5.6 trillion USD assets under management on Augus...
BAUDETTE, Minn. , Jan. 24, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Tolterodine Extended-Release Capsules, 2 mg and 4 mg. The current annual U.S. market for this product is approximately $101 million , according to IQ...
BAUDETTE, Minn. , Jan. 16, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced it has received approval of the Company's abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) for Potassium Citrate Extended-Release T...
BAUDETTE, Minn. , Jan. 14, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg and 9 mg. The current annual U.S. market for this product is approximately $342 million , accordin...
BAUDETTE, Minn. , Jan. 9, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the acquisition of the U.S. portfolio of 23 generic products from Amerigen Pharmaceuticals, Ltd. for $52.5M in cash at close and up to $25M in contingent profit share p...
News, Short Squeeze, Breakout and More Instantly...
ANI Pharmaceuticals Inc. Company Name:
ANIP Stock Symbol:
NASDAQ Market:
ANI Pharmaceuticals Inc. Website:
PRINCETON, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched L-Glutamine Oral Po...
2024-07-09 17:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) and launched Naproxen Delayed-Release Tablets, USP....